
Network Bio is a biotechnology company building disease-specific AI models from human biological data to support the personalized practice of medicine. Through collaborations with U.S.-based academic medical centers, the company has connected data spanning immunology, metabolic, cardiovascular, auto-immune disease, among others. By integrating this biological foundation with AI purpose-built for medicine, Network Bio is developing technologies designed to accelerate diagnostics, biomarker discovery and drug development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/26 | $50,000,000 |
Blue Venture Fund Breyer Capital Founders Fund JSL Health Capital Section 32 Thiel Bio | undisclosed |